

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.7	89.7	(32.8-195.2)	Male	6	4.7	128.6	(47.0-280.0)
Female	3	2.4	nc	(nc-nc)	Female	7	3.8	186.4	(74.7-384.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	25	27.2	91.8	(59.4-135.6)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9.4	106.2	(50.8-195.3)	Female	2	2.6	nc	(nc-nc)
Female	9	8.4	107.4	(49.0-203.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.1	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	27.3	128.0	(89.2-178.1)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.1	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.4	nc	(nc-nc)	Female	5	6.0	83.7	(27.0-195.2)
Female	0	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	95.1	97.8	(78.9-119.8)
Male	1	1.9	nc	(nc-nc)	Female	87	89.7	96.9	(77.6-119.6)
Female	2	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	12.6	63.6	(27.4-125.4)					
Female	11	11.9	92.3	(46.0-165.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	19.8	101.1	(61.7-156.1)	Male	16	12.8	125.0	(71.4-202.9)
Female	5	8.0	62.7	(20.2-146.3)	Female	23	11.1	207.0	(131.2-310.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.9	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	10.9	55.1	(20.1-119.9)
Female	73	80.1	91.1	(71.4-114.6)	Female	11	10.4	106.3	(53.0-190.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.3	nc	(nc-nc)	Male	6	8.0	75.3	(27.5-163.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	26.9	115.2	(78.3-163.6)	Female	8	8.0	99.5	(42.8-196.0)
Female	31	28.4	109.3	(74.2-155.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	6.1	nc	(nc-nc)
Male	5	5.3	94.3	(30.4-220.1)	Female	5	6.9	72.0	(23.2-168.1)
Female	1	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	77	75.6	101.9	(80.4-127.4)
Male	3	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.1	nc	(nc-nc)
Male	13	10.0	129.9	(69.1-222.1)	<u>Testis</u>				
Female	1	6.4	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.2	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	12	12.3	97.3	(50.2-170.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.7	89.0	(32.5-193.7)	Female	13	17.8	73.2	(38.9-125.1)
Female	4	5.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	262	266.5	98.3	(86.8-111.0)
Male	5	5.1	98.0	(31.6-228.7)	Female	264	277.2	95.2	(84.1-107.5)
Female	3	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	36.1	96.9	(67.5-134.7)					
Female	43	38.1	112.9	(81.7-152.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	101	102.6	98.5	(80.2-119.6)	Male	77	61.8	124.6	(98.3-155.7)
Female	38	38.0	100.1	(70.8-137.3)	Female	59	50.4	117.1	(89.1-151.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	18.5	97.2	(57.6-153.7)	Male	17	15.8	107.9	(62.8-172.7)
Female	19	15.6	121.5	(73.1-189.7)	Female	10	12.1	82.5	(39.5-151.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	3.1	nc	(nc-nc)	Male	67	53.7	124.8	(96.7-158.5)
Female	431	359.9	119.8	(108.7-131.6)	Female	60	48.7	123.2	(94.0-158.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	14.5	34.4	(11.1-80.3)	Male	26	36.8	70.7	(46.2-103.6)
Female					Female	22	18.2	121.2	(75.9-183.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	114	135.1	84.4	(69.6-101.4)	Female	44	36.8	119.5	(86.8-160.4)
Female	116	134.2	86.4	(71.4-103.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	31	30.9	100.3	(68.1-142.4)
Male	14	25.7	54.5	(29.8-91.4)	Female	32	33.1	96.6	(66.0-136.3)
Female	6	7.2	83.1	(30.4-180.9)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	379	362.8	104.5	(94.2-115.5)
Male	5	7.8	64.4	(20.8-150.4)	<u>Stomach</u>				
Female	3	6.6	nc	(nc-nc)	Male	22	23.8	92.4	(57.9-140.0)
<u>Kidney & Renal Pelvis</u>					Female	12	14.9	80.4	(41.5-140.4)
Male	47	47.8	98.3	(72.2-130.7)	<u>Testis</u>				
Female	37	29.6	124.9	(88.0-172.2)	Male	16	11.9	134.6	(76.9-218.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	15.2	59.1	(27.0-112.1)	Male	31	16.3	190.2	(129.2-270.0)
Female	5	4.4	114.4	(36.9-267.1)	Female	81	54.2	149.4	(118.7-185.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	22	34.2	64.3	(40.3-97.3)	Female	95	79.8	119.1	(96.4-145.6)
Female	23	26.4	87.0	(55.1-130.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1231	1312.9	93.8	(88.6-99.2)
Male	17	23.9	71.0	(41.3-113.7)	Female	1331	1278.1	104.1	(98.6-109.9)
Female	4	8.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	104	182.9	56.9	(46.5-68.9)					
Female	141	180.4	78.2	(65.8-92.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.6	104.8	(45.1-206.5)	Male	7	6.8	103.2	(41.4-212.7)
Female	4	1.9	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.5	127.1	(50.9-262.0)
Female	30	26.2	114.4	(77.1-163.3)	Female	6	2.7	218.3	(79.7-475.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.8	101.6	(52.4-177.5)	Female	3	2.4	nc	(nc-nc)
Female	4	6.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	2.6	351.9	(160.6-668.0)
Male	2	2.4	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	34.3	113.6	(80.8-155.3)
Male	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	8	5.2	155.2	(66.8-305.9)	<u>Testis</u>				
Female	2	1.9	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	13	4.9	263.4	(140.1-450.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	11	5.6	195.2	(97.3-349.3)
Female	2	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	136	123.7	109.9	(92.2-130.1)
Male	3	2.7	nc	(nc-nc)	Female	113	81.3	139.0	(114.5-167.1)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	14.8	87.7	(46.6-149.9)					
Female	14	9.6	145.2	(79.3-243.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	17.6	136.4	(87.3-202.9)	Male	11	10.3	107.1	(53.4-191.6)
Female	3	7.7	nc	(nc-nc)	Female	3	8.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	9.0	66.8	(24.4-145.5)
Female	45	62.9	71.6	(52.2-95.8)	Female	8	9.5	84.5	(36.4-166.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.3	nc	(nc-nc)	Male	6	6.0	100.7	(36.8-219.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	22.6	114.8	(75.0-168.3)	Female	5	6.7	74.8	(24.1-174.6)
Female	28	26.7	104.8	(69.6-151.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	5.2	171.7	(78.3-325.9)
Male	6	4.3	139.3	(50.9-303.1)	Female	11	6.7	164.5	(82.0-294.4)
Female	4	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	78	61.2	127.4	(100.7-159.0)
Male	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.2	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	8	3.0	264.5	(113.9-521.2)
Male	8	7.9	100.8	(43.4-198.6)	<u>Testis</u>				
Female	6	5.5	108.2	(39.5-235.5)	Male	4	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.6	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	5	8.6	58.3	(18.8-136.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	5.8	121.3	(48.6-250.0)	Female	14	14.0	100.3	(54.8-168.2)
Female	4	5.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	271	221.5	122.3	(108.2-137.8)
Male	1	3.9	nc	(nc-nc)	Female	221	237.4	93.1	(81.2-106.2)
Female	0	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	31.5	168.2	(126.0-220.0)					
Female	47	35.7	131.7	(96.8-175.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	28.4	116.1	(79.9-163.1)	Male	18	18.0	100.2	(59.4-158.4)
Female	17	11.6	146.9	(85.5-235.2)	Female	20	15.3	130.9	(79.9-202.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.6	106.5	(38.9-231.7)	Male	5	4.4	112.7	(36.3-262.9)
Female	4	4.8	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	14	15.6	89.9	(49.1-150.8)
Female	124	106.9	116.0	(96.5-138.3)	Female	14	14.9	94.1	(51.4-157.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.5	nc	(nc-nc)	Male	9	10.8	83.6	(38.1-158.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	38	38.1	99.8	(70.6-136.9)	Female	12	11.0	109.0	(56.2-190.3)
Female	37	41.8	88.4	(62.3-121.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.6	81.0	(32.4-166.9)
Male	13	7.3	179.2	(95.3-306.4)	Female	12	10.2	117.9	(60.9-206.0)
Female	2	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	114	101.3	112.6	(92.9-135.3)
Male	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	5	2.0	247.1	(79.6-576.6)	Male	8	6.7	119.7	(51.5-235.9)
<u>Kidney & Renal Pelvis</u>					Female	5	4.7	105.6	(34.0-246.3)
Male	10	13.8	72.6	(34.8-133.6)	<u>Testis</u>				
Female	9	8.8	102.3	(46.7-194.2)	Male	4	3.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	4.3	nc	(nc-nc)	Male	8	5.0	160.4	(69.1-316.0)
Female	0	1.3	nc	(nc-nc)	Female	12	16.4	73.3	(37.9-128.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	10.0	69.8	(28.0-143.9)	Female	22	23.1	95.3	(59.7-144.3)
Female	8	8.3	96.4	(41.5-190.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	389	371.6	104.7	(94.5-115.6)
Male	4	6.9	nc	(nc-nc)	Female	411	385.1	106.7	(96.6-117.5)
Female	3	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	48	50.4	95.2	(70.2-126.2)					
Female	47	53.2	88.4	(64.9-117.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	23.3	55.8	(29.7-95.4)	Male	25	16.4	152.1	(98.4-224.5)
Female	9	8.6	104.2	(47.5-197.8)	Female	19	14.1	134.5	(80.9-210.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.4	147.9	(63.7-291.4)	Male	2	3.8	nc	(nc-nc)
Female	5	4.4	114.5	(36.9-267.2)	Female	3	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	13.9	122.3	(71.2-195.9)
Female	114	95.5	119.3	(98.4-143.3)	Female	8	11.8	68.0	(29.3-134.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.6	nc	(nc-nc)	Male	6	10.1	59.6	(21.8-129.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	32.4	89.5	(59.9-128.5)	Female	6	9.4	63.6	(23.2-138.4)
Female	38	30.6	124.1	(87.8-170.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	7.3	68.5	(22.1-159.7)
Male	5	6.4	77.9	(25.1-181.7)	Female	6	7.4	80.7	(29.5-175.6)
Female	3	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	91.1	96.6	(77.5-119.0)
Male	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.1	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	3.4	nc	(nc-nc)
Male	13	12.6	103.2	(54.9-176.5)	<u>Testis</u>				
Female	8	7.4	108.0	(46.5-212.9)	Male	3	4.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	3.8	130.0	(41.9-303.4)	Male	5	5.1	98.5	(31.8-229.9)
Female	1	1.1	nc	(nc-nc)	Female	18	17.3	104.0	(61.6-164.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	8.7	68.9	(25.1-149.9)	Female	19	20.8	91.4	(55.0-142.8)
Female	6	6.7	89.6	(32.7-195.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	326	328.0	99.4	(88.9-110.8)
Male	6	6.3	95.1	(34.7-206.9)	Female	348	323.2	107.7	(96.6-119.6)
Female	0	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	58	43.1	134.6	(102.2-174.1)					
Female	43	42.1	102.0	(73.8-137.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	13	18.3	71.0	(37.7-121.3)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	6.9	86.7	(31.7-188.7)	Female	0	1.8	nc	(nc-nc)
Female	6	6.3	94.6	(34.5-205.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	18.7	53.5	(25.6-98.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	9.4	53.4	(17.2-124.7)	Male	43	68.1	63.1	(45.7-85.0)
Female	4	9.0	nc	(nc-nc)	Female	45	63.8	70.5	(51.5-94.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	13.3	128.3	(74.7-205.4)	Male	12	9.2	130.3	(67.3-227.6)
Female	7	4.6	151.9	(60.9-313.0)	Female	12	7.2	166.6	(86.0-291.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.7	129.6	(62.1-238.4)
Female	61	51.6	118.2	(90.4-151.8)	Female	6	6.2	97.0	(35.4-211.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	18.4	103.2	(62.1-161.2)	Female	6	5.0	119.0	(43.5-259.1)
Female	12	15.9	75.5	(38.9-131.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.2	119.0	(38.3-277.6)
Male	6	3.8	159.9	(58.4-348.1)	Female	4	3.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	71	54.6	130.1	(101.6-164.1)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.7	nc	(nc-nc)
Male	12	7.3	165.2	(85.3-288.6)	<u>Testis</u>				
Female	3	4.0	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.3	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	12	8.7	138.6	(71.5-242.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	4.8	104.1	(33.5-242.9)	Female	6	11.5	52.2	(19.1-113.6)
Female	4	3.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	224	188.6	118.8	(103.7-135.4)
Male	2	3.7	nc	(nc-nc)	Female	183	171.8	106.5	(91.7-123.2)
Female	3	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	25.1	87.5	(54.8-132.5)					
Female	16	23.1	69.3	(39.6-112.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	31.0	77.5	(49.6-115.3)	Male	19	19.2	98.9	(59.5-154.4)
Female	11	12.7	86.9	(43.3-155.6)	Female	14	17.4	80.7	(44.1-135.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	87.1	(28.1-203.3)	Male	8	4.8	166.2	(71.5-327.4)
Female	4	5.3	nc	(nc-nc)	Female	6	4.0	149.8	(54.7-326.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	18	16.6	108.5	(64.3-171.5)
Female	120	115.7	103.7	(86.0-124.0)	Female	16	16.4	97.4	(55.6-158.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.9	121.3	(44.3-264.0)	Male	12	11.5	104.1	(53.7-181.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	41.3	94.5	(67.2-129.2)	Female	11	12.2	90.2	(45.0-161.5)
Female	39	45.9	85.0	(60.5-116.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.4	63.8	(23.3-139.0)
Male	10	7.9	126.7	(60.6-233.0)	Female	18	11.1	161.8	(95.8-255.7)
Female	5	2.4	209.5	(67.5-489.0)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	110	110.9	99.2	(81.6-119.6)
Male	3	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.9	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	5.2	nc	(nc-nc)
Male	15	14.8	101.4	(56.7-167.2)	<u>Testis</u>				
Female	7	9.6	73.2	(29.3-150.8)	Male	5	4.3	116.6	(37.6-272.0)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.7	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	12	18.9	63.6	(32.8-111.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	10.4	77.0	(33.1-151.7)	Female	27	25.2	107.1	(70.5-155.8)
Female	7	9.0	77.8	(31.2-160.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	364	402.4	90.5	(81.4-100.3)
Male	5	7.5	66.9	(21.6-156.1)	Female	391	422.6	92.5	(83.6-102.2)
Female	0	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	42	55.3	75.9	(54.7-102.6)					
Female	46	57.9	79.4	(58.1-105.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	12.3	65.1	(28.0-128.3)	Male	6	8.9	67.5	(24.6-146.8)
Female	3	4.4	nc	(nc-nc)	Female	9	7.3	123.2	(56.2-233.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.4	nc	(nc-nc)
Female	61	51.3	118.8	(90.9-152.6)	Female	3	6.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	5	5.7	88.0	(28.3-205.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	17.4	91.9	(52.5-149.2)	Female	5	5.0	100.5	(32.4-234.5)
Female	27	15.3	176.3	(116.2-256.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.9	nc	(nc-nc)
Male	1	3.6	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	52	51.5	100.9	(75.4-132.3)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	1.7	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.9	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	9.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.6	nc	(nc-nc)	Female	11	11.3	97.7	(48.7-174.8)
Female	1	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	155	179.0	86.6	(73.5-101.4)
Male	4	3.6	nc	(nc-nc)	Female	178	168.6	105.6	(90.7-122.3)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	23.4	76.8	(45.5-121.4)					
Female	18	21.9	82.2	(48.7-130.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.5	96.5	(52.7-162.0)	Male	9	9.1	98.4	(44.9-186.7)
Female	4	6.0	nc	(nc-nc)	Female	4	7.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.9	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.9	113.4	(51.8-215.3)
Female	66	54.6	120.9	(93.5-153.9)	Female	11	7.7	142.8	(71.2-255.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	5	5.4	92.3	(29.7-215.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	19.3	103.4	(63.1-159.7)	Female	7	5.6	123.9	(49.6-255.4)
Female	14	21.8	64.3	(35.1-107.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	4.4	136.3	(49.8-296.7)
Male	4	3.7	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	51.1	115.4	(87.8-148.9)
Male	4	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.5	nc	(nc-nc)
Male	5	7.0	71.4	(23.0-166.6)	<u>Testis</u>				
Female	4	4.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	10	8.5	118.3	(56.6-217.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.1	98.1	(31.6-228.9)	Female	13	11.8	110.2	(58.6-188.5)
Female	3	4.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	187	188.8	99.1	(85.4-114.3)
Male	2	3.5	nc	(nc-nc)	Female	194	198.7	97.6	(84.4-112.4)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	25.7	77.7	(47.5-120.1)					
Female	28	27.5	101.9	(67.7-147.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	13	13.2	98.5	(52.4-168.4)	Female	1	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.0	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	5	4.5	110.8	(35.7-258.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	21	14.2	148.2	(91.7-226.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.8	nc	(nc-nc)	Female	7	2.9	238.2	(95.4-490.8)
Female	1	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Male	48	49.4	97.1	(71.6-128.7)
Female	0	0.2	nc	(nc-nc)	Female	44	45.4	97.0	(70.5-130.2)
<u>Leukemia</u>									
Male	0	1.3	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.9	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	6.7	nc	(nc-nc)					
Female	3	6.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	13.2	60.8	(26.2-119.8)	Male	11	9.8	111.9	(55.8-200.2)
Female	3	5.1	nc	(nc-nc)	Female	18	8.9	203.1	(120.3-321.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.4	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	8.3	nc	(nc-nc)
Female	52	58.0	89.7	(67.0-117.6)	Female	8	7.1	112.3	(48.3-221.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.9	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	18.8	170.4	(116.5-240.5)	Female	7	5.8	121.4	(48.6-250.2)
Female	9	18.3	49.1	(22.4-93.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	4.2	nc	(nc-nc)
Male	5	3.8	132.6	(42.7-309.4)	Female	3	4.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	55	53.6	102.6	(77.3-133.5)
Male	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	12	7.5	159.9	(82.5-279.4)	<u>Testis</u>				
Female	5	4.4	112.8	(36.3-263.1)	Male	5	3.0	165.7	(53.4-386.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.3	nc	(nc-nc)	Male	5	3.2	157.9	(50.9-368.5)
Female	1	0.6	nc	(nc-nc)	Female	8	11.1	71.8	(30.9-141.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.2	95.8	(30.9-223.6)	Female	13	12.6	103.4	(55.0-176.9)
Female	3	4.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	206	192.5	107.0	(92.9-122.7)
Male	4	3.8	nc	(nc-nc)	Female	193	196.1	98.4	(85.0-113.4)
Female	0	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	34	24.6	138.5	(95.9-193.5)					
Female	23	24.6	93.6	(59.3-140.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	11.8	168.8	(103.1-260.7)	Male	15	7.7	194.1	(108.5-320.1)
Female	2	4.3	nc	(nc-nc)	Female	11	5.9	185.2	(92.3-331.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	39	43.8	89.1	(63.4-121.9)	Female	7	5.5	126.2	(50.6-260.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	5.0	121.1	(44.2-263.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	16.2	117.2	(70.5-183.1)	Female	6	4.4	137.1	(50.1-298.5)
Female	19	15.1	125.7	(75.7-196.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.7	nc	(nc-nc)
Male	4	3.3	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	47.5	84.2	(60.2-114.7)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.7	nc	(nc-nc)
Male	6	6.1	97.9	(35.8-213.1)	<u>Testis</u>				
Female	7	3.5	202.8	(81.2-417.8)	Male	0	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.0	nc	(nc-nc)	Male	5	2.1	232.8	(75.0-543.2)
Female	0	0.5	nc	(nc-nc)	Female	11	6.6	167.4	(83.4-299.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.1	nc	(nc-nc)	Female	10	9.9	101.2	(48.5-186.2)
Female	6	3.0	197.1	(72.0-429.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	165	162.8	101.3	(86.5-118.0)
Male	3	3.1	nc	(nc-nc)	Female	159	149.7	106.2	(90.4-124.1)
Female	2	1.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	22.0	77.4	(45.1-124.0)					
Female	19	20.4	93.3	(56.2-145.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	36.8	70.7	(46.2-103.6)	Male	24	21.8	110.3	(70.6-164.1)
Female	17	14.6	116.8	(68.0-186.9)	Female	21	17.9	117.5	(72.7-179.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	6.5	200.7	(106.7-343.2)	Male	3	5.6	nc	(nc-nc)
Female	8	5.6	142.1	(61.2-280.0)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	20	18.9	105.8	(64.6-163.3)
Female	115	127.2	90.4	(74.7-108.6)	Female	16	18.2	88.0	(50.3-143.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	5.0	119.0	(43.5-259.0)	Male	11	12.6	87.6	(43.7-156.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	60	47.6	126.1	(96.3-162.4)	Female	18	13.2	136.1	(80.6-215.1)
Female	40	50.7	78.9	(56.3-107.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	11.0	127.3	(69.5-213.6)
Male	13	9.0	143.7	(76.4-245.7)	Female	11	12.6	87.1	(43.4-155.9)
Female	1	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	117	127.6	91.7	(75.8-109.9)
Male	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.2	nc	(nc-nc)	Male	6	8.5	70.8	(25.8-154.1)
<u>Kidney & Renal Pelvis</u>					Female	10	5.7	174.6	(83.6-321.2)
Male	16	16.8	95.4	(54.5-154.9)	<u>Testis</u>				
Female	11	10.9	101.0	(50.4-180.7)	Male	10	4.4	225.2	(107.8-414.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	11	5.3	205.7	(102.5-368.0)	Male	1	5.7	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	17	18.5	92.1	(53.6-147.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	12.1	82.6	(39.6-152.0)	Female	29	28.2	102.7	(68.8-147.5)
Female	11	9.9	111.2	(55.4-198.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	469	464.0	101.1	(92.1-110.6)
Male	7	8.2	85.6	(34.3-176.4)	Female	485	467.0	103.9	(94.8-113.5)
Female	3	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	67	65.6	102.1	(79.1-129.7)					
Female	89	68.5	129.8	(104.3-159.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.2	141.8	(51.8-308.7)	Male	3	2.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	18	16.5	108.8	(64.4-171.9)	Female	3	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	5.7	105.7	(38.6-230.1)	Female	1	1.7	nc	(nc-nc)
Female	3	6.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.4	nc	(nc-nc)	Male	24	15.8	152.2	(97.5-226.5)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	2.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	5	1.4	344.9	(111.2-804.9)	Male	0	0.8	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	5	2.4	204.2	(65.8-476.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.1	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	7.8	103.1	(44.4-203.2)	Male	73	56.4	129.3	(101.4-162.6)
Female	5	8.6	58.4	(18.8-136.4)	Female	58	59.0	98.4	(74.7-127.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.5	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	6	6.0	99.4	(36.3-216.4)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	5	6.2	81.2	(26.2-189.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	2.8	176.1	(56.8-411.0)	Female	23	22.1	103.9	(65.9-155.9)
Female	0	2.2	nc	(nc-nc)	Female	14	18.8	74.4	(40.7-124.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.6	128.3	(63.9-229.5)	Male	2	5.4	nc	(nc-nc)
Female	5	3.2	157.2	(50.6-366.8)	Female	1	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	129.7	(47.4-282.4)
Female	17	30.8	55.2	(32.1-88.3)	Female	2	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.4	104.9	(54.1-183.2)	Female	0	3.1	nc	(nc-nc)
Female	8	11.1	72.3	(31.1-142.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	32.6	73.7	(47.2-109.7)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.9	nc	(nc-nc)	Female	13	7.0	186.8	(99.4-319.5)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	93	114.3	81.4	(65.7-99.7)
Male	0	2.1	nc	(nc-nc)	Female	79	108.6	72.7	(57.6-90.6)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	15.8	114.0	(67.5-180.1)					
Female	16	15.4	104.0	(59.4-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	17.1	140.3	(89.9-208.8)	Male	11	8.6	128.4	(64.0-229.8)
Female	9	6.0	150.4	(68.6-285.6)	Female	6	5.7	104.5	(38.2-227.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	5	7.7	65.3	(21.1-152.5)
Female	55	44.6	123.2	(92.8-160.4)	Female	8	7.1	113.2	(48.8-223.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	4.8	125.9	(46.0-274.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	20.9	110.0	(69.7-165.1)	Female	7	4.8	145.4	(58.2-299.5)
Female	19	20.5	92.6	(55.7-144.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	3.9	nc	(nc-nc)	Male	7	4.9	142.0	(56.9-292.6)
Female	2	1.2	nc	(nc-nc)	Female	2	5.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	7	6.7	103.8	(41.6-213.8)	Male	0	0.7	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.3	nc	(nc-nc)	Female	13	10.2	127.4	(67.8-217.9)
Female	1	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.0	121.0	(44.2-263.4)	Male	230	197.9	116.2	(101.7-132.2)
Female	3	3.6	nc	(nc-nc)	Female	181	173.2	104.5	(89.8-120.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	21	30.0	70.1	(43.4-107.1)	<u>All Sites / Types</u>				
Female	18	27.9	64.4	(38.2-101.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	3	5.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	8.0	75.3	(27.5-164.0)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	3	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	2	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	26	27.3	95.2	(62.2-139.5)
Male	0	0.5	nc	(nc-nc)	Female	17	19.2	88.7	(51.6-142.0)
Female	1	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.8	nc	(nc-nc)					
Female	2	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	12.6	142.8	(84.6-225.7)	Male	5	8.6	58.5	(18.8-136.4)
Female	8	4.6	174.7	(75.2-344.2)	Female	6	7.1	84.1	(30.7-183.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	5	2.2	225.5	(72.7-526.3)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	11	7.3	151.7	(75.6-271.5)
Female	50	49.4	101.1	(75.1-133.4)	Female	5	6.1	81.5	(26.3-190.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.3	nc	(nc-nc)	Male	11	5.2	209.7	(104.5-375.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	17.3	80.9	(44.2-135.8)	Female	4	4.9	nc	(nc-nc)
Female	17	15.9	107.0	(62.3-171.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.9	127.6	(41.1-297.7)
Male	4	3.4	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	36	48.7	73.9	(51.7-102.3)
Male	4	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.7	nc	(nc-nc)
Male	8	6.6	121.0	(52.1-238.3)	<u>Testis</u>				
Female	1	3.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.0	nc	(nc-nc)	Male	9	2.5	353.1	(161.1-670.3)
Female	1	0.6	nc	(nc-nc)	Female	3	8.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	4.6	nc	(nc-nc)	Female	8	10.8	73.9	(31.8-145.5)
Female	3	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	194	174.0	111.5	(96.3-128.3)
Male	4	3.3	nc	(nc-nc)	Female	162	167.8	96.5	(82.2-112.6)
Female	1	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	32	23.2	137.6	(94.1-194.3)					
Female	25	22.7	110.0	(71.2-162.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	14.6	102.8	(57.5-169.5)	Male	7	9.0	77.4	(31.0-159.6)
Female	9	6.0	151.1	(69.0-286.9)	Female	8	7.6	105.9	(45.6-208.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.8	89.4	(35.8-184.1)
Female	43	53.6	80.3	(58.1-108.2)	Female	6	7.5	79.5	(29.0-173.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	6	5.4	111.7	(40.8-243.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	19.3	77.5	(43.4-127.9)	Female	3	5.5	nc	(nc-nc)
Female	21	20.9	100.3	(62.1-153.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	3.7	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	5	5.2	96.3	(31.0-224.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	43	52.4	82.1	(59.4-110.6)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	7	7.0	99.7	(40.0-205.5)	Male	3	3.4	nc	(nc-nc)
Female	6	4.5	132.4	(48.4-288.3)	Female	1	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	4	2.2	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	5.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	8	8.0	100.3	(43.2-197.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.5	nc	(nc-nc)	Female	13	11.7	111.1	(59.1-190.0)
Female	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	31	26.4	117.6	(79.9-167.0)	Male	170	189.9	89.5	(76.6-104.0)
Female	22	28.0	78.5	(49.2-118.9)	Female	175	194.5	90.0	(77.1-104.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.7	139.8	(60.2-275.5)	Male	3	3.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	18	17.2	104.8	(62.1-165.7)	Female	2	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.7	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.5	80.1	(29.3-174.4)	Female	2	1.7	nc	(nc-nc)
Female	7	5.8	121.2	(48.5-249.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	16	20.7	77.1	(44.1-125.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	5	3.8	130.8	(42.2-305.3)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Male	58	73.9	78.5	(59.6-101.5)
Female	0	0.2	nc	(nc-nc)	Female	57	59.3	96.1	(72.8-124.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	6	10.4	57.7	(21.1-125.7)	<u>All Sites / Types</u>				
Female	6	8.4	71.5	(26.1-155.7)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	83	66.8	124.3	(99.0-154.1)	Male	35	40.3	86.9	(60.5-120.8)
Female	33	25.5	129.4	(89.0-181.7)	Female	42	31.7	132.7	(95.6-179.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	12.0	125.5	(70.2-206.9)	Male	9	10.3	87.7	(40.0-166.5)
Female	8	10.0	80.0	(34.5-157.7)	Female	13	8.0	161.7	(86.0-276.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.0	nc	(nc-nc)	Male	41	34.6	118.4	(84.9-160.6)
Female	248	231.8	107.0	(94.1-121.2)	Female	49	32.0	153.0	(113.1-202.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	8.9	78.5	(31.5-161.8)	Male	17	24.3	70.1	(40.8-112.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	100	87.3	114.5	(93.2-139.3)	Female	22	23.8	92.4	(57.9-139.9)
Female	90	87.8	102.5	(82.4-126.0)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	12	17.1	70.1	(36.2-122.4)	Male	226	247.2	91.4	(79.9-104.2)
Female	5	4.9	102.7	(33.1-239.7)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	4.8	nc	(nc-nc)	Male	3	7.4	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	41	31.6	129.7	(93.1-176.0)	Female	63	52.2	120.7	(92.7-154.4)
Female	27	19.6	137.6	(90.6-200.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	10.2	127.0	(67.6-217.2)	Male	930	867.0	107.3	(100.5-114.4)
Female	2	2.9	nc	(nc-nc)	Female	986	833.3	118.3	(111.1-125.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	44	21.9	201.0	(146.0-269.8)	<u>All Sites / Types</u>				
Female	30	17.2	174.7	(117.9-249.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	15.7	114.6	(67.9-181.2)	<u>All Sites / Types</u>				
Female	7	5.7	122.0	(48.9-251.5)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	136	122.0	111.5	(93.5-131.9)	<u>All Sites / Types</u>				
Female	160	122.8	130.3	(110.9-152.1)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	7	6.0	116.7	(46.8-240.5)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	6	7.2	82.8	(30.2-180.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.5	nc	(nc-nc)	Male	16	24.7	64.6	(36.9-105.0)
Female	0	0.1	nc	(nc-nc)	Female	22	19.3	113.9	(71.4-172.5)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	3.4	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	14.9	107.2	(61.2-174.1)	Male	11	10.9	101.0	(50.4-180.8)
Female	4	5.2	nc	(nc-nc)	Female	10	8.8	113.5	(54.3-208.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	15	9.0	166.2	(93.0-274.2)
Female	68	61.9	109.9	(85.4-139.4)	Female	7	7.2	97.4	(39.0-200.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.9	nc	(nc-nc)	Male	13	7.0	186.0	(98.9-318.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	21.1	123.2	(80.4-180.5)	Female	5	6.0	83.4	(26.9-194.5)
Female	17	17.9	95.1	(55.4-152.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	4.4	114.4	(36.9-267.0)	Male	74	64.5	114.7	(90.1-144.1)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.6	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	8.5	105.8	(48.3-200.8)	Female	18	13.9	129.1	(76.5-204.1)
Female	4	4.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.7	nc	(nc-nc)	Female	18	13.9	129.1	(76.5-204.1)
Female	0	0.7	nc	(nc-nc)	Male	251	219.9	114.1	(100.5-129.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	5.6	nc	(nc-nc)	Female	211	202.7	104.1	(90.5-119.1)
Female	1	4.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.3	nc	(nc-nc)	Male	251	219.9	114.1	(100.5-129.2)
Female	0	1.3	nc	(nc-nc)	Female	211	202.7	104.1	(90.5-119.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	37	28.5	129.7	(91.3-178.7)	Male	251	219.9	114.1	(100.5-129.2)
Female	36	26.6	135.3	(94.7-187.3)	Female	211	202.7	104.1	(90.5-119.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	7.9	152.4	(78.7-266.2)	Male	3	6.1	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.1	118.2	(43.1-257.2)
Female	41	36.2	113.3	(81.3-153.6)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	6	3.8	156.5	(57.2-340.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	11.5	104.5	(53.9-182.6)	Female	3	3.5	nc	(nc-nc)
Female	2	10.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	3	2.3	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	32.6	92.0	(62.1-131.4)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.8	nc	(nc-nc)	Male	5	1.9	259.9	(83.8-606.5)
<u>Kidney & Renal Pelvis</u>					Female	2	1.2	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	5	2.7	184.2	(59.4-429.9)	Male	3	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	0.4	nc	(nc-nc)	Female	7	6.7	104.6	(41.9-215.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.2	nc	(nc-nc)	Female	9	7.8	115.4	(52.7-219.1)
Female	5	2.4	205.0	(66.1-478.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	124	117.4	105.6	(87.8-125.9)
Male	2	2.4	nc	(nc-nc)	Female	130	118.4	109.8	(91.8-130.4)
Female	4	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	14.9	113.7	(66.2-182.1)					
Female	17	14.9	114.1	(66.4-182.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	6	2.5	242.2	(88.4-527.2)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	3.4	148.6	(47.9-346.8)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	9	12.0	74.8	(34.1-142.0)
Male	0	0.2	nc	(nc-nc)	Female	10	7.8	128.5	(61.5-236.3)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	7	5.2	133.3	(53.4-274.7)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	9	6.0	150.0	(68.4-284.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	2.7	nc	(nc-nc)	Female	20	21.4	93.6	(57.1-144.5)
Female	5	2.0	248.0	(79.9-578.7)	Female	20	16.7	119.7	(73.1-184.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	78	59.6	130.9	(103.5-163.4)	Male	38	34.6	109.8	(77.7-150.7)
Female	20	23.8	84.2	(51.4-130.0)	Female	37	28.1	131.7	(92.7-181.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	10.2	146.6	(82.0-241.8)	Male	8	9.0	89.2	(38.4-175.8)
Female	7	8.9	78.4	(31.4-161.6)	Female	3	7.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.8	nc	(nc-nc)	Male	33	30.2	109.2	(75.2-153.4)
Female	210	203.0	103.4	(89.9-118.4)	Female	24	29.5	81.3	(52.1-121.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	7.7	143.3	(71.4-256.4)	Male	23	20.1	114.4	(72.5-171.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	95	76.7	123.8	(100.2-151.4)	Female	14	21.3	65.9	(36.0-110.5)
Female	79	82.9	95.3	(75.5-118.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	26	17.8	146.3	(95.5-214.4)
Male	16	14.6	109.5	(62.6-177.9)	Female	22	20.7	106.0	(66.4-160.5)
Female	9	4.5	198.4	(90.5-376.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	187	207.2	90.2	(77.8-104.1)
Male	3	4.3	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.4	nc	(nc-nc)	Male	8	13.7	58.6	(25.2-115.5)
<u>Kidney & Renal Pelvis</u>					Female	5	9.3	53.6	(17.3-125.1)
Male	26	26.8	97.0	(63.4-142.2)	<u>Testis</u>				
Female	14	17.6	79.7	(43.5-133.7)	Male	11	6.5	169.6	(84.5-303.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	8.7	80.9	(32.4-166.7)	Male	6	8.8	68.4	(25.0-148.8)
Female	2	2.6	nc	(nc-nc)	Female	22	28.0	78.5	(49.2-118.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	19.4	98.0	(59.0-153.1)	Female	44	45.4	97.0	(70.5-130.2)
Female	11	15.9	69.1	(34.4-123.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	772	747.7	103.2	(96.1-110.8)
Male	17	13.2	129.1	(75.2-206.8)	Female	774	751.3	103.0	(95.9-110.5)
Female	7	5.3	132.1	(52.9-272.1)					
<u>Lung and Bronchus</u>									
Male	109	106.5	102.4	(84.1-123.5)					
Female	140	111.6	125.4	(105.5-148.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	3	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	0.4	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	10	11.6	86.4	(41.4-158.9)
Female	0	0.1	nc	(nc-nc)	Female	9	8.0	112.3	(51.2-213.1)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	8.3	108.8	(49.6-206.5)	Male	3	5.4	nc	(nc-nc)
Female	4	2.9	nc	(nc-nc)	Female	5	4.2	118.3	(38.1-276.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.6	130.2	(47.5-283.3)
Female	23	30.2	76.1	(48.2-114.2)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	11.1	90.0	(43.1-165.5)	Female	1	3.0	nc	(nc-nc)
Female	7	10.0	69.8	(28.0-143.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.6	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	44	32.0	137.5	(99.9-184.5)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	6	4.2	141.5	(51.7-308.1)	<u>Testis</u>				
Female	4	2.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.3	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Female	9	6.8	132.8	(60.6-252.2)
Female	1	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	131	112.7	116.3	(97.2-138.0)
Male	1	2.1	nc	(nc-nc)	Female	89	104.0	85.5	(68.7-105.3)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	15.4	103.9	(59.4-168.8)					
Female	15	14.7	102.4	(57.3-168.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	53.8	102.2	(77.0-133.0)	Male	66	35.7	184.7	(142.8-234.9)
Female	22	20.0	109.8	(68.8-166.2)	Female	47	29.0	162.3	(119.3-215.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.3	79.4	(36.3-150.8)	Male	10	8.6	116.6	(55.8-214.4)
Female	10	9.0	111.0	(53.1-204.1)	Female	8	6.5	123.9	(53.4-244.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.7	nc	(nc-nc)	Male	30	30.5	98.3	(66.3-140.3)
Female	241	203.3	118.5	(104.0-134.5)	Female	32	26.4	121.0	(82.8-170.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	10	8.7	114.4	(54.8-210.5)	Male	25	21.7	115.0	(74.4-169.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	89	73.4	121.2	(97.4-149.2)	Female	21	20.5	102.5	(63.4-156.7)
Female	72	71.4	100.9	(78.9-127.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	19	16.6	114.3	(68.8-178.4)
Male	13	14.3	90.9	(48.3-155.4)	Female	19	17.4	109.0	(65.6-170.2)
Female	4	3.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	280	202.9	138.0	(122.3-155.2)
Male	5	5.3	93.8	(30.2-218.8)	<u>Stomach</u>				
Female	10	3.9	258.4	(123.7-475.2)	Male	14	12.7	110.0	(60.1-184.6)
<u>Kidney & Renal Pelvis</u>					Female	4	7.9	nc	(nc-nc)
Male	34	27.4	124.1	(85.9-173.4)	<u>Testis</u>				
Female	30	16.3	184.6	(124.5-263.5)	Male	8	9.0	88.9	(38.3-175.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	9	8.5	105.4	(48.1-200.0)	Male	9	10.4	86.5	(39.5-164.2)
Female	3	2.4	nc	(nc-nc)	Female	32	32.8	97.5	(66.7-137.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	20	19.3	103.7	(63.3-160.2)	Female	58	44.9	129.0	(98.0-166.8)
Female	26	14.7	177.3	(115.8-259.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	890	730.7	121.8	(113.9-130.1)
Male	17	13.8	123.1	(71.7-197.1)	Female	826	705.8	117.0	(109.2-125.3)
Female	8	4.7	169.1	(72.8-333.2)					
<u>Lung and Bronchus</u>									
Male	128	97.8	130.9	(109.2-155.7)					
Female	107	95.9	111.6	(91.5-134.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	5	1.7	294.7	(95.0-687.7)
Female	0	0.7	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	11	9.5	116.0	(57.8-207.6)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	0.7	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	14	10.0	140.1	(76.5-235.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.7	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	4.3	nc	(nc-nc)	Female	44	33.9	129.7	(94.3-174.2)
Female	5	3.6	137.7	(44.4-321.4)	Female	32	29.9	106.9	(73.1-151.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.9	263.0	(84.8-613.8)
Female	15	12.4	120.7	(67.5-199.1)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	4.5	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	16	13.1	122.6	(70.0-199.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Male	46	45.5	101.2	(74.1-134.9)
Female	0	0.1	nc	(nc-nc)	Female	35	38.9	89.9	(62.6-125.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	5.9	85.3	(27.5-199.2)	<u>All Sites / Types</u>				
Female	0	4.8	nc	(nc-nc)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	5.1	213.7	(106.6-382.5)	Male	6	3.3	183.5	(67.0-399.4)
Female	2	1.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	2.8	215.1	(78.6-468.2)
Female	16	15.8	101.1	(57.7-164.2)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	7	2.0	357.7	(143.3-737.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	6.9	216.4	(121.0-356.9)	Female	1	1.6	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	1.6	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	18	18.5	97.5	(57.8-154.1)
Male	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.7	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.7	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	103	67.2	153.2	(125.1-185.8)
Male	6	1.3	472.4	(172.5-1028.2)	Female	51	56.6	90.1	(67.1-118.4)
Female	0	0.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	9.2	108.6	(52.0-199.8)					
Female	14	8.0	175.9	(96.1-295.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	95	106.8	88.9	(71.9-108.7)	Male	74	65.6	112.8	(88.5-141.6)
Female	52	42.9	121.2	(90.5-158.9)	Female	57	55.3	103.0	(78.0-133.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	19.7	106.6	(66.0-163.0)	Male	15	16.4	91.6	(51.2-151.1)
Female	16	17.1	93.6	(53.5-152.0)	Female	15	13.5	111.2	(62.2-183.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.2	nc	(nc-nc)	Male	53	56.4	94.0	(70.4-122.9)
Female	353	386.3	91.4	(82.1-101.4)	Female	59	54.3	108.6	(82.7-140.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	15.9	131.7	(81.5-201.4)	Male	49	38.2	128.4	(95.0-169.8)
Female					Female	22	19.9	110.3	(69.1-167.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	140	139.8	100.1	(84.2-118.2)	Female	41	40.0	102.6	(73.6-139.2)
Female	175	149.4	117.1	(100.4-135.8)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	31	26.9	115.4	(78.4-163.9)	Male	31	32.2	96.4	(65.5-136.8)
Female	6	8.2	73.4	(26.8-159.8)	Female	38	37.2	102.1	(72.2-140.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	9.0	99.6	(45.4-189.0)	Male	281	382.9	73.4	(65.1-82.5)
Female	8	7.3	110.2	(47.4-217.1)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	48	50.1	95.7	(70.6-126.9)	Male	36	24.8	145.4	(101.8-201.4)
Female	26	32.7	79.4	(51.9-116.3)	Female	15	16.8	89.5	(50.1-147.7)
<u>Larynx</u>					<u>Testis</u>				
Male	17	16.0	106.3	(61.9-170.1)	Male	14	15.4	91.0	(49.7-152.7)
Female	9	4.8	187.0	(85.3-355.0)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	27	35.7	75.7	(49.9-110.1)	Male	11	17.8	61.8	(30.8-110.5)
Female	30	29.4	102.1	(68.9-145.8)	Female	62	59.1	104.8	(80.4-134.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	40	24.6	162.3	(116.0-221.1)	Female	90	85.9	104.8	(84.2-128.8)
Female	12	9.7	123.8	(63.9-216.2)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	184	192.6	95.6	(82.2-110.4)	Male	1285	1380.6	93.1	(88.1-98.3)
Female	239	203.9	117.2	(102.8-133.1)	Female	1464	1405.7	104.1	(98.9-109.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	33.8	88.6	(59.8-126.5)	Male	15	21.7	69.1	(38.7-114.0)
Female	13	12.5	104.1	(55.4-178.1)	Female	14	17.9	78.1	(42.7-131.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.8	132.5	(60.5-251.6)	Male	5	5.3	94.1	(30.3-219.6)
Female	4	5.6	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	27	18.6	145.3	(95.7-211.4)
Female	132	125.4	105.3	(88.1-124.8)	Female	18	16.3	110.4	(65.4-174.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.4	nc	(nc-nc)	Male	8	13.1	61.0	(26.3-120.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	42	45.4	92.6	(66.7-125.2)	Female	22	12.6	174.3	(109.2-263.9)
Female	58	43.5	133.4	(101.3-172.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	10.4	115.6	(59.7-201.9)
Male	7	8.9	78.9	(31.6-162.6)	Female	16	10.8	148.7	(84.9-241.5)
Female	0	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	118	126.3	93.4	(77.3-111.9)
Male	3	3.0	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2.4	nc	(nc-nc)	Male	8	7.9	101.1	(43.5-199.2)
<u>Kidney & Renal Pelvis</u>					Female	13	4.8	270.4	(143.8-462.4)
Male	18	16.8	107.0	(63.4-169.1)	<u>Testis</u>				
Female	9	10.1	88.7	(40.5-168.5)	Male	0	4.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.3	nc	(nc-nc)	Male	7	6.1	114.3	(45.8-235.5)
Female	2	1.5	nc	(nc-nc)	Female	20	20.5	97.5	(59.5-150.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	11.8	76.4	(34.8-145.0)	Female	34	27.8	122.4	(84.7-171.0)
Female	6	9.0	66.6	(24.3-144.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	454	451.8	100.5	(91.5-110.2)
Male	9	8.4	107.0	(48.8-203.1)	Female	481	436.8	110.1	(100.5-120.4)
Female	1	2.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	76	61.8	122.9	(96.8-153.8)					
Female	77	60.6	127.1	(100.3-158.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.8	108.7	(60.8-179.3)	Male	12	8.9	134.3	(69.3-234.5)
Female	1	5.2	nc	(nc-nc)	Female	9	7.4	121.1	(55.2-229.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.6	104.7	(45.1-206.3)
Female	50	52.7	94.8	(70.4-125.0)	Female	2	6.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	8	5.5	145.5	(62.6-286.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	18.7	117.9	(73.9-178.5)	Female	7	5.3	132.1	(52.9-272.2)
Female	12	18.2	65.9	(34.0-115.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.3	117.1	(37.7-273.3)
Male	4	3.7	nc	(nc-nc)	Female	0	4.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	65	52.7	123.2	(95.1-157.1)
Male	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.0	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.0	nc	(nc-nc)
Male	11	7.0	157.7	(78.6-282.1)	<u>Testis</u>				
Female	2	4.3	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.2	nc	(nc-nc)	Male	4	2.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	8	8.4	94.8	(40.8-186.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.8	nc	(nc-nc)	Female	6	11.8	50.9	(18.6-110.9)
Female	3	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	207	186.5	111.0	(96.4-127.2)
Male	3	3.5	nc	(nc-nc)	Female	156	182.8	85.4	(72.5-99.9)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	25.4	78.9	(48.2-121.8)					
Female	28	25.3	110.7	(73.5-160.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	26.5	102.0	(67.2-148.4)	Male	18	16.7	107.9	(63.9-170.6)
Female	18	10.1	179.0	(106.0-282.9)	Female	13	13.5	96.3	(51.2-164.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	5.2	173.6	(79.2-329.6)	Male	4	4.1	nc	(nc-nc)
Female	4	4.3	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	12	14.3	83.8	(43.2-146.3)
Female	138	98.2	140.5	(118.0-166.0)	Female	15	12.9	116.4	(65.1-192.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.0	nc	(nc-nc)	Male	12	10.1	119.1	(61.5-208.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	35.3	93.5	(64.4-131.4)	Female	9	9.9	91.1	(41.6-172.9)
Female	44	34.9	125.9	(91.5-169.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	8.1	86.4	(34.6-178.1)
Male	2	6.9	nc	(nc-nc)	Female	9	8.7	103.7	(47.3-196.8)
Female	3	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	115	98.0	117.4	(96.9-140.9)
Male	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.6	nc	(nc-nc)	Male	6	6.2	97.4	(35.5-211.9)
<u>Kidney & Renal Pelvis</u>					Female	6	3.9	155.1	(56.6-337.5)
Male	10	13.1	76.5	(36.6-140.7)	<u>Testis</u>				
Female	6	8.0	74.7	(27.3-162.7)	Male	4	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.1	nc	(nc-nc)	Male	5	4.6	107.9	(34.8-251.8)
Female	0	1.2	nc	(nc-nc)	Female	22	14.8	148.2	(92.9-224.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	9.1	55.2	(17.8-128.7)	Female	18	21.8	82.7	(49.0-130.7)
Female	8	7.1	113.3	(48.8-223.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	346	350.0	98.9	(88.7-109.9)
Male	6	6.5	92.3	(33.7-201.0)	Female	389	343.2	113.3	(102.4-125.2)
Female	2	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	43	48.5	88.7	(64.2-119.5)					
Female	36	48.6	74.1	(51.9-102.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.4	135.1	(73.8-226.6)	Male	13	7.4	174.9	(93.0-299.1)
Female	7	3.5	198.3	(79.4-408.6)	Female	4	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	6.2	112.8	(45.2-232.3)
Female	45	41.5	108.5	(79.1-145.1)	Female	6	4.8	124.7	(45.5-271.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	14.8	88.1	(46.9-150.7)	Female	4	4.0	nc	(nc-nc)
Female	10	12.4	80.7	(38.7-148.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.3	149.9	(48.3-349.9)
Male	3	3.0	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	43.6	123.9	(93.1-161.6)
Male	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.3	nc	(nc-nc)
Male	5	5.9	85.1	(27.4-198.7)	<u>Testis</u>				
Female	4	3.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	7.1	98.3	(39.4-202.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.8	131.8	(42.5-307.5)	Female	8	9.2	87.2	(37.6-171.9)
Female	7	2.6	264.4	(105.9-544.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	157	150.5	104.3	(88.6-122.0)
Male	5	3.0	164.7	(53.1-384.4)	Female	138	135.7	101.7	(85.5-120.2)
Female	2	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	19.7	66.1	(35.2-113.1)					
Female	16	17.6	90.7	(51.8-147.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	55.1	103.5	(78.4-134.1)	Male	23	33.3	69.1	(43.8-103.7)
Female	32	21.1	151.6	(103.7-214.0)	Female	34	27.0	126.0	(87.2-176.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	10.1	79.1	(34.0-155.8)	Male	10	8.3	119.8	(57.3-220.3)
Female	10	8.6	117.0	(56.0-215.1)	Female	6	6.6	91.0	(33.2-198.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	31	28.8	107.7	(73.2-152.9)
Female	190	188.0	101.1	(87.2-116.5)	Female	33	26.7	123.8	(85.2-173.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	11	7.9	139.6	(69.6-249.7)	Male	19	19.1	99.6	(59.9-155.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	79	71.4	110.7	(87.6-138.0)	Female	20	19.5	102.7	(62.7-158.7)
Female	76	73.2	103.9	(81.8-130.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	16.5	102.9	(59.9-164.8)
Male	10	13.7	73.0	(35.0-134.3)	Female	19	18.2	104.2	(62.7-162.8)
Female	4	4.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	174	194.1	89.7	(76.8-104.0)
Male	9	4.5	199.9	(91.2-379.4)	<u>Stomach</u>				
Female	4	3.5	nc	(nc-nc)	Male	12	12.7	94.6	(48.8-165.2)
<u>Kidney & Renal Pelvis</u>					Female	14	8.2	170.0	(92.9-285.3)
Male	36	25.5	141.1	(98.8-195.4)	<u>Testis</u>				
Female	27	16.1	167.8	(110.5-244.1)	Male	10	7.6	132.2	(63.3-243.1)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	8.1	160.0	(85.1-273.6)	Male	10	8.9	112.1	(53.7-206.2)
Female	1	2.4	nc	(nc-nc)	Female	30	29.0	103.6	(69.9-147.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	18.4	86.8	(49.6-140.9)	Female	44	41.7	105.5	(76.7-141.7)
Female	19	14.6	129.8	(78.1-202.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	743	704.0	105.5	(98.1-113.4)
Male	14	12.4	113.3	(61.9-190.1)	Female	787	688.0	114.4	(106.5-122.7)
Female	8	4.8	167.8	(72.2-330.6)					
<u>Lung and Bronchus</u>									
Male	134	99.1	135.2	(113.2-160.1)					
Female	137	100.2	136.7	(114.8-161.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	9	8.0	112.2	(51.2-212.9)	Female	2	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	18	9.5	190.2	(112.6-300.6)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.2	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	4	4.3	nc	(nc-nc)	Male	40	31.4	127.3	(90.9-173.3)
Female	0	3.8	nc	(nc-nc)	Female	27	27.0	100.0	(65.9-145.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.7	149.9	(60.1-308.9)	Male	4	3.4	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	17	18.6	91.3	(53.2-146.2)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	6.7	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	19	19.7	96.5	(58.1-150.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	6	4.1	147.4	(53.8-320.8)
Female	2	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Male	62	68.3	90.7	(69.6-116.3)
Female	1	0.2	nc	(nc-nc)	Female	54	60.1	89.8	(67.5-117.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	5	8.8	56.5	(18.2-131.9)	<u>All Sites / Types</u>				
Female	7	7.7	91.2	(36.6-188.0)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	17.9	100.6	(59.6-159.0)	Male	15	11.5	130.7	(73.1-215.5)
Female	10	7.3	137.5	(65.8-252.9)	Female	9	10.0	89.7	(41.0-170.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.6	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.5	nc	(nc-nc)	Male	13	9.8	132.3	(70.4-226.3)
Female	70	71.1	98.5	(76.7-124.4)	Female	9	9.4	96.0	(43.8-182.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	23.8	121.6	(81.4-174.6)	Female	8	7.2	111.1	(47.8-218.9)
Female	27	24.8	108.7	(71.6-158.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.5	nc	(nc-nc)
Male	10	4.7	213.1	(102.0-391.9)	Female	11	6.2	176.9	(88.2-316.5)
Female	0	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	67.5	87.4	(66.5-112.7)
Male	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	2.7	nc	(nc-nc)
Male	18	8.9	201.7	(119.5-318.8)	<u>Testis</u>				
Female	2	5.9	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.8	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	12	11.2	106.7	(55.1-186.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.3	159.7	(76.4-293.6)	Female	18	16.0	112.5	(66.6-177.8)
Female	4	5.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	264	240.0	110.0	(97.1-124.1)
Male	6	4.4	136.1	(49.7-296.2)	Female	266	249.7	106.5	(94.1-120.1)
Female	1	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	33	33.1	99.8	(68.7-140.2)					
Female	48	35.7	134.4	(99.1-178.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	11.8	161.3	(97.1-251.9)	Male	11	6.8	161.4	(80.4-288.7)
Female	5	4.7	106.2	(34.2-247.8)	Female	6	5.6	107.3	(39.2-233.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	5.9	117.8	(47.2-242.6)
Female	36	42.1	85.6	(59.9-118.5)	Female	3	5.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	21	15.4	136.6	(84.5-208.8)	Female	7	4.3	161.6	(64.7-332.9)
Female	14	16.6	84.6	(46.2-141.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.5	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	5	4.1	121.3	(39.1-283.1)
Female	2	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	40.9	102.6	(73.9-138.7)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	1.8	nc	(nc-nc)
Male	1	5.3	nc	(nc-nc)	<u>Testis</u>				
Female	4	3.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	10	9.4	106.0	(50.7-194.9)
Female	1	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	162	147.3	109.9	(93.7-128.2)
Male	0	2.7	nc	(nc-nc)	Female	138	151.5	91.1	(76.5-107.6)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	20.8	105.9	(66.4-160.4)					
Female	25	22.3	112.3	(72.7-165.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	8.0	125.6	(60.1-231.0)
Male	0	0.1	nc	(nc-nc)	Female	12	6.4	188.7	(97.4-329.7)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	1.1	nc	(nc-nc)					
Female	2	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	4.7	148.8	(59.6-306.6)	Male	2	3.4	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	21	20.4	103.0	(63.7-157.4)	Female	4	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	6.7	119.5	(51.5-235.5)	Female	2	2.0	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	1	0.5	nc	(nc-nc)	Female	22	18.6	118.0	(73.9-178.7)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	2.6	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.8	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.3	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	8.7	57.5	(18.5-134.2)	Female	75	67.4	111.3	(87.6-139.5)
Female	13	8.7	148.7	(79.1-254.3)	Female	59	68.3	86.3	(65.7-111.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	1.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	4.9	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	15	17.5	85.9	(48.0-141.7)
Male	0	0.4	nc	(nc-nc)	Female	6	14.6	41.0	(15.0-89.2)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	2.3	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;